mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumab

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3033940 50 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
mRNA expression of specific HER ligands and their association with
clinical outcome in patients with metastatic breast cancer treated with
trastuzumab
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Prognostic and predictive biomarkers are being studied for the diagnosis
and treatment of breast cancer. The present study retrospectively
assessed the mRNA expression of HER family receptor ligands and of other
potential prognostic biomarkers and their association with time to
progression (TTP), survival and clinicopathological characteristics in
patients with metastatic breast cancer (MBC) treated with trastuzumab. A
total of 145 tumour tissue samples were analysed. mRNA expression
analysis of the transcripts of interest was performed and the
association of these markers with selected clinicopathological
parameters was examined. HER2 status was centrally re-evaluated. Only
67.6% of patients were truly HER2-positive according to the central
HER2 re-evaluation. Heparin binding epidermal growth factor (EGF)-like
growth factor, transforming growth factor beta 1 (TGFB1) and thyroid
hormone receptor alpha (THRA) mRNA expression was higher in
HER2-positive patients (P=0.026, P<0.001 and P<0.001). Insulin-like
growth factor binding protein 4 was correlated with retinoic acid
receptor alpha, TGFB1 and THRA (rho=0.45, rho=0.60 and rho=0.45). In
HER2-positive patients, high neuregulin 1 and high betacellulin were
unfavourable factors for TTP [hazard ratio (HR) = 1.78, P=0.040 and
HR=2.00, P=0.043, respectively]. In patients with de novo MBC, high EGF
expression was associated with a non-significant prolongation of TTP
(HR=0.52, P=0.080) and significantly longer survival (HR=0.40, P=0.020).
The present study examined clinical and biological implications of
specific genes and it was concluded that their expression has an impact
on the outcome of trastuzumab-treated patients with MBC.
Έτος δημοσίευσης:
2022
Συγγραφείς:
Rapti, Vassiliki
Moirogiorgou, Evangelia
Koliou,
Georgia-Angeliki
Papadopoulou, Kyriaki
Binas, Ioannis and
Pentheroudakis, George
Bafaloukos, Dimitrios
Bobos, Mattheos and
Chatzopoulos, Kyriakos
Chrisafi, Sofia
Christodoulou, Christos
and Nicolaou, Irene
Sotiropoulou, Maria
Magkou, Christina and
Koutras, Angelos
Papakostas, Pavlos
Kotsakis, Athanasios and
Razis, Evangelia
Psyrri, Amanda
Tryfonopoulos, Dimitrios and
Pectasides, Dimitrios
Res, Eleni
Alexopoulos, Athanasios and
Kotoula, Vassiliki
Fountzilas, George
Περιοδικό:
Oncology Letters
Εκδότης:
SPANDIDOS PUBL LTD
Τόμος:
23
Αριθμός / τεύχος:
1
Λέξεις-κλειδιά:
metastatic breast cancer; trastuzumab; biomarkers; HER2; HER ligands
Επίσημο URL (Εκδότης):
DOI:
10.3892/ol.2021.13141
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.